Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Coral wrecks Sage
Approval for zuranolone might be in reach, but meeting sales expectations could be a different story.
Neurocrine provides some good news in Huntington’s
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
Biotech’s key fourth-quarter data
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Cancer continues to dominate deal making
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
